Ahmad Farooq
State Key Laboratory of Chemistry and Utilization of Carbon Based Energy Resources, College of Chemistry, Xinjiang University, Urumqi 830017, China.
Biomater Res. 2025 Feb 25;29:0145. doi: 10.34133/bmr.0145. eCollection 2025.
Cancer remains a major concern for human health worldwide. To fight the curse of cancer, boron neutron capture therapy is an incredibly advantageous modality in the treatment of cancer as compared to other radiotherapies. Due to tortuous vasculature in and around tumor regions, boron (B) compounds preferentially house into tumor cells, creating a large dose gradient between the highly mingled cancer cells and normal cells. Epithermal or thermal neutron bombardment leads to tumor-cell-selective killing due to the generation of heavy particles yielded from in situ fission reaction. However, the major challenges for boron nanocomposites' development have been from the synthesis part as well as the requirement for selective cancer targeting and the delivery of therapeutic concentrations of boron (B) with nominal healthy tissue accumulation and retention. To circumvent the above challenges, this review discusses boride nanocomposite design, safety, and biocompatibility for biomedical applications for general public use. This review sparks interest in using boron nanocomposites as boron neutron capture therapy agents and repurposing them in comorbidity treatments, with future scientific challenges and opportunities, with a hope to accelerate the stimulus of developing possible boron composite nanomedicine research and applications worldwide.
癌症仍然是全球人类健康的一大主要担忧。为对抗癌症的诅咒,与其他放射疗法相比,硼中子俘获疗法在癌症治疗中是一种极具优势的方式。由于肿瘤区域及其周围血管曲折,硼(B)化合物优先聚集在肿瘤细胞中,在高度混合的癌细胞和正常细胞之间形成大剂量梯度。超热或热中子轰击会因原位裂变反应产生的重粒子而导致肿瘤细胞选择性杀伤。然而,硼纳米复合材料发展的主要挑战来自合成部分,以及选择性癌症靶向的要求和以名义上健康组织积累和保留的方式递送治疗浓度的硼(B)。为规避上述挑战,本综述讨论了用于一般公众生物医学应用的硼化物纳米复合材料的设计、安全性和生物相容性。本综述激发了将硼纳米复合材料用作硼中子俘获疗法药物并将其重新用于合并症治疗的兴趣,以及未来的科学挑战和机遇,希望能加速全球范围内开发可能的硼复合纳米医学研究和应用的刺激。